Subscribe
designer491
designer491 / iStockphoto.com
19 January 2018Americas

Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs

Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Allergan tries to escape Restasis IPRs
10 January 2018   Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).
Americas
Allergan deal with tribe could kill off IPR: Bryson
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Allergan tries to escape Restasis IPRs
10 January 2018   Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).
Americas
Allergan deal with tribe could kill off IPR: Bryson
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.

More on this story

Big Pharma
Allergan tries to escape Restasis IPRs
10 January 2018   Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).
Americas
Allergan deal with tribe could kill off IPR: Bryson
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB